GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (OTCPK:LPCUF) » Definitions » Debt-to-Revenue

LPCUF (Lee's Pharmaceutical Holdings) Debt-to-Revenue : 0.15 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Lee's Pharmaceutical Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Lee's Pharmaceutical Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $20.3 Mil. Lee's Pharmaceutical Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $8.9 Mil. Lee's Pharmaceutical Holdings's annualized Revenue for the quarter that ended in Dec. 2024 was $190.8 Mil. Lee's Pharmaceutical Holdings's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.15.


Lee's Pharmaceutical Holdings Debt-to-Revenue Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Debt-to-Revenue Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.21 0.13 0.19 0.16

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.20 0.19 0.19 0.15

Competitive Comparison of Lee's Pharmaceutical Holdings's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Debt-to-Revenue falls into.


;
;

Lee's Pharmaceutical Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Lee's Pharmaceutical Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(20.295 + 8.946) / 180.097
=0.16

Lee's Pharmaceutical Holdings's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(20.295 + 8.946) / 190.81
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


Lee's Pharmaceutical Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines